Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02855086 · ClinicalTrials.gov registry record · Phase 1
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
A Phase 1 study, sponsored by Eben Rosenthal.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02855086 is a Phase 1 study that was terminated before completion, run by Eben Rosenthal. The registered enrollment target is 3 participants.
The verdict
NCT02855086, a Phase 1 study, was terminated before completion, sponsored by Eben Rosenthal.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is a phase 1-2 trial that evaluates the best dose of cetuximab-IRDye 800CW and how well it works in detecting tumors in patients with malignant glioma who are undergoing surgery. Cetuximab-IRDye 800CW is an optical imaging agent that may help detect tumor cells when a special camera is used.
Interventions
- BIOLOGICAL Cetuximab
- PROCEDURE Tumor resection
- DRUG Cetuximab-IRDye 800CW
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-10 |
| Est. Completion | 2016-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02855086
The ClinicalTrials.gov registry entry for NCT02855086 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eben Rosenthal, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT02855086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02855086 about?
NCT02855086 is a clinical study titled "Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery". This study is a phase 1-2 trial that evaluates the best dose of cetuximab-IRDye 800CW and how well it works in detecting tumors in patients with malignant glioma who are undergoing surgery. Cetuximab-IRDye 800CW is an optical imaging agent that may help detect tumor cells when a special camera is us...
What is the current status of trial NCT02855086?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2016-10. Estimated completion is 2016-11-22.
What interventions are being tested in trial NCT02855086?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Tumor resection (PROCEDURE), Cetuximab-IRDye 800CW (DRUG).
Who is sponsoring clinical trial NCT02855086?
This trial is sponsored by Eben Rosenthal, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.